OXIS International, Inc. Share Price Other OTC
Equities
US6918294025
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
26/03 | GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01/02 | GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.29M 358M |
---|---|---|---|---|---|
Net income 2024 * | -17M -1.42B | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.29
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.75% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 62 | 13/21/13 |
Manu Ohri
DFI | Director of Finance/CFO | 67 | 18/22/18 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 14/22/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 01/23/01 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 11/20/11 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 13/21/13 |
1st Jan change | Capi. | |
---|---|---|
+34.00% | 664B | |
+29.29% | 567B | |
-7.75% | 354B | |
+18.53% | 330B | |
+4.95% | 286B | |
+13.79% | 234B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.89% | 148B |